aXichem obtains patent for phenylcapsaicin for use in the treatment of idiopathic pulmonary fibrosis
aXichem AB (publ) (“aXichem”), that develops and markets analogue industrial compounds, announces that the company has received patent protection for the company's unique product, phenylcapsaicin, for use in the treatment of idiopathic pulmonary fibrosis (IPF). “This is a strategically interesting patent for aXichem and it strengthens the patent portfolio in an excellent way in an area where the need for effective treatment is great. My hope is that in the future this patent will have commercial significance for the company and that phenylcapsaicin, with its